Although these historic challenges with development of MAPK-based combinations for treatment of RAS-mutant cancers do not negate the importance of investigating SHP2–MAPK combinations in the clinic, they did motivate the focus of this study to query for additional potential targets that may effectively combine with SHP2 in the KRAS-amp state. This evidence concerns the gene PTPN11 and cancer.